OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single‐dose treatment from a phase III, randomized, double‐blind, placebo‐controlled trial (interim analysis)
暂无分享,去创建一个
Y. Tanahashi | Terukazu Nakamura | A. Kawauchi | N. Kawata | Satoru Takahashi | K. Fujii | C. Ohyama | M. Kinjo | I. Sasagawa | N. Seki | H. Okuno | N. Sawada | Y. Funahashi | T. Fukagai | T. Yamanishi | A. Mizokami | O. Yokoyama | T. Kitta | A. Takenaka | H. Sakai | Y. Ishiura | Toyohiko Watanabe | N. Ninomiya | K. Miwa | Yasuyo Yamamoto | K. Sagiyama | Toshihiko Saito | M. Honda | T. Itoi | T. Kawai | N. Okuno | M. Ootani | A. Otsuka | Y. Matsuta | Yasutomo Suzuki | A. Takahashi | H. Ikeda | M. Tobiume | M. Kawahara | Masaki Yoshida | H. Matsushima | N. Tokuda | H. Tomoe | H. Nishimura | Chie Matsushita | H. Sasaki | Y. Sekiguchi | T. Nakayama | N. Ishito | F. Nakajima | K. Kambe | Takeshi Watanabe | K. Suyama | F. Manabe | E. Nozawa | Takao Mogi | S. Kanegae
[1] Tomomi Kimura,et al. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real‐world analysis , 2017, International journal of urology : official journal of the Japanese Urological Association.
[2] J. Juel,et al. Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003–2012 in a Danish population , 2017, Scandinavian journal of urology.
[3] V. Nitti,et al. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. , 2016, The Journal of urology.
[4] T. Uchiyama,et al. Neuromodulation for the Treatment of Lower Urinary Tract Symptoms , 2015, Lower urinary tract symptoms.
[5] C. Nardo,et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. , 2013, European urology.
[6] N. Hinata,et al. Botulinum toxin type A injection for neurogenic detrusor overactivity: Clinical outcome in Japanese patients , 2013, International journal of urology : official journal of the Japanese Urological Association.
[7] K. Burgio,et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. , 2012, The Journal of urology.
[8] Y. Homma,et al. Botulinum toxin A submucosal injection for refractory non‐neurogenic overactive bladder: Early outcomes , 2011, International journal of urology : official journal of the Japanese Urological Association.
[9] K. Coyne,et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature , 2011, International journal of clinical practice.
[10] Rui Pinto,et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. , 2010, European urology.
[11] S. de Wachter,et al. Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review , 2010, Urologia Internationalis.
[12] K. Sugaya,et al. [Economic impact of overactive bladder symptoms in Japan]. , 2008, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
[13] S. Colman,et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. , 2008, Urology.
[14] Y. Homma,et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. , 2006, Urology.
[15] P. Abrams,et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well‐being in six European countries , 2006, BJU international.
[16] Y. Homma,et al. An epidemiological survey of overactive bladder symptoms in Japan , 2005, BJU international.
[17] D. Cockayne,et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. , 2005, The Journal of urology.
[18] W. Stewart,et al. Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.
[19] Magnus Fall,et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.
[20] P. Abrams,et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.
[21] C. Kelleher,et al. Overactive bladder significantly affects quality of life. , 2000, The American journal of managed care.
[22] L. Cardozo,et al. A new questionnaire to assess the quality of life of urinary incontinent women , 1997, British journal of obstetrics and gynaecology.
[23] Xiaohong Yan,et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. , 2013, The Journal of urology.
[24] M. Saito,et al. Experience with injections of botulinum toxin type A into the detrusor muscle. , 2010, Aktuelle Urologie.
[25] D. Staskin,et al. Surgical options for drug-refractory overactive bladder patients. , 2010, Reviews in urology.